Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS

PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. today announced the initiation of a global early access program (EAP) for ulefnersen, an investigational RNA-targeted medicine, for eligible people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene1, who have a confirmed genetic diagnosis and meet predefined program eligibility criteria. FUS-ALS is a rare fo